Poolbeg’s new Chief Business Officer: A Leader in Life Sciences with a record of success

If you do a google search on Poolbeg Pharma’s (LON:POLB) new chief business officer David Allmond you’ll find appearances on the GB News TV channel discussing pandemics and monkeypox detection in his previous role as Novacyte CEO, you’ll read about not insignificant share purchases and board trusteeships for entities such as Global Action for Fungal Infections. Allmond is in demand as charities and institutions tap into his over two decades immersion in life sciences. There’s no doubt that he can pick and choose, but he has chosen to adhere to a network that he has much history with. The network he is aligned to has form in terms of shareholder value creation and real world medical success. That team were involved with Amryt Pharma which last year was bought by Italy’s Chiesi Farmaceutici S.p.A for $1.48 billion.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

AI-powered drug discovery is changing the future of medicine

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

The Medicine of Tomorrow

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for